Who is sponsoring NCT05360615?

NCT05360615 is sponsored by Chulalongkorn University.

What drugs are being tested in NCT05360615?

Interventions in NCT05360615: Empagliflozin 10 MG, Placebo.

What condition does NCT05360615 study?

NCT05360615 studies Empagliflozin in Post AKI Stage 2-3.

Is NCT05360615 still recruiting?

NCT05360615 is currently active, enrolled. Last updated 17 August 2025.

Last reviewed 2025-08-17 · How we verify

NCT05360615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Active, enrolled Phase 1 Last updated 17 August 2025

What this trial tests

Phase 1 trial testing Empagliflozin 10 MG in Empagliflozin in Post AKI Stage 2-3 in 147 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 July 2022

Primary endpoint
1 June 2024

1 July 2026

Quick facts

Lead sponsor	Chulalongkorn University
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	147
Start date	1 July 2022
Primary completion	1 June 2024
Estimated completion	1 July 2026
Sites	1 location across Thailand

Drugs / interventions tested

Empagliflozin 10 MG — full drug profile →
Placebo

Conditions studied

Empagliflozin in Post AKI Stage 2-3 — all drugs for Empagliflozin in Post AKI Stage 2-3 →

Sponsor

Chulalongkorn University

Who can join

18 and older, any sex, with Empagliflozin in Post AKI Stage 2-3. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SGLT2 Inhibitors and Long-Term Outcomes After AKI.
Wannakittirat A, Nimkietkajorn V, Thanapongsathorn P, Chaijamorn W, et al · · 2026 · PMID 41684789 · DOI 10.1016/j.ekir.2025.103752
What Are the Impacts of Introducing an SGLT2 Inhibitor after a Recent Episode of Acute Kidney Injury?
Proença de Moraes T. · · 2024 · PMID 38546982 · DOI 10.34067/kid.0000000000000386

Verify or expand the search:

Other trials of Empagliflozin 10 MG

Trials testing the same drug.

NCT03867487 — SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
NCT06706791 — Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II · Phase 4 · recruiting
NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
NCT06030843 — The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 · Phase 2, PHASE3 · recruiting

Other Chulalongkorn University trials

Trials by the same sponsor.

NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05360615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
Last refreshed: 17 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05360615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing